Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Total Liabilities (2018 - 2025)

Neurogene's Total Liabilities history spans 6 years, with the latest figure at $23.7 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 6.46% year-over-year to $23.7 million; the TTM value through Dec 2025 reached $23.7 million, down 6.46%, while the annual FY2025 figure was $23.7 million, 6.46% down from the prior year.
  • Total Liabilities reached $23.7 million in Q4 2025 per NGNE's latest filing, up from $22.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $36.5 million in Q4 2023 to a low of $14.4 million in Q3 2023.
  • Average Total Liabilities over 3 years is $23.1 million, with a median of $23.9 million recorded in 2025.
  • The largest YoY upside for Total Liabilities was 86.09% in 2024 against a maximum downside of 30.63% in 2024.
  • A 3-year view of Total Liabilities shows it stood at $36.5 million in 2023, then tumbled by 30.63% to $25.4 million in 2024, then fell by 6.46% to $23.7 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Total Liabilities are $23.7 million (Q4 2025), $22.3 million (Q3 2025), and $24.1 million (Q2 2025).